Eli Lilly (NYSE:LLY) is one of the most prominent drugmakers on the globe. However, with a market cap exceeding $62 billion and product offerings in a wide range of therapeutic areas, it can be difficult for investors to understand every aspect of its business. In this segment, health care analyst Max Macaluso takes a close look at a specific division that generated more than $2 billion in revenue last year but that many Lilly investors might not know about: animal health.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.